Compare WSM & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WSM | INSM |
|---|---|---|
| Founded | 1956 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Home Furnishings | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.0B | 23.0B |
| IPO Year | 1995 | 2000 |
| Metric | WSM | INSM |
|---|---|---|
| Price | $206.37 | $99.08 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 24 |
| Target Price | ★ $209.71 | $201.17 |
| AVG Volume (30 Days) | 1.1M | ★ 4.2M |
| Earning Date | 05-21-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.68% | N/A |
| EPS Growth | ★ 0.57 | N/A |
| EPS | ★ 1.93 | N/A |
| Revenue | ★ $7,806,816,000.00 | N/A |
| Revenue This Year | $5.37 | $182.31 |
| Revenue Next Year | $4.50 | $65.19 |
| P/E Ratio | $107.91 | ★ N/A |
| Revenue Growth | ★ 1.24 | N/A |
| 52 Week Low | $152.20 | $70.57 |
| 52 Week High | $221.81 | $212.75 |
| Indicator | WSM | INSM |
|---|---|---|
| Relative Strength Index (RSI) | 66.08 | 30.73 |
| Support Level | $188.34 | $98.90 |
| Resistance Level | $220.67 | $166.81 |
| Average True Range (ATR) | 6.58 | 3.92 |
| MACD | 2.34 | 0.56 |
| Stochastic Oscillator | 90.78 | 5.36 |
With a retail and direct-to-consumer presence, Williams-Sonoma is a player in the nearly $300 billion domestic home category and $450 billion international home market, focused on expanding its exposure in the B2B ($80 billion total addressable market), marketplace, and franchise areas. Namesake Williams-Sonoma (153 stores) offers high-end cooking essentials, while Pottery Barn (180) provides casual home accessories. West Elm (116) is an emerging concept for young professionals, and Rejuvenation (13) offers lighting and house parts. Brand extensions include Pottery Barn Kids and Pottery Barn Teen (43) as well as Mark & Graham and GreenRow. Williams-Sonoma also has a business-to-business team that supports projects that range from residential to large-scale commercial.
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.